ANTIBODY TO ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) LEVEL DETERMINES CLINICAL RESPONSE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) TO DMARD THERAPY

T.P. Khreshchakova , V.K. Grin , A.M. Gnylorybov , V.A. Melokhina , A.A. Zaplotnaya Laboratory for Fundamental Research, Cardiosurgery Dept., Institute of urgent and recovery Surgery, Chair of Family Medicine, Immunology Dept, State Medical University, Donetsk, UkraineCitation: Ann Rheum Dis, volume 66, supplement II, year 2007, page 592Session: RA – epidemiology, prognosis and predictors